Despite recent decreases in reimbursement, it remains an exciting time to practice ophthalmology thanks to innovation in pharmaceuticals for the anterior and posterior segments, novel drug delivery systems, ocular imaging, and minimally invasive anterior and posterior segment surgery. Furthermore, the drug development pipeline is robust and bullish for anterior segment disease. Here is a review of many promising medications in development (Table).

CORNEA
Dry Eye Therapy

Eleven Biotherapeutics is developing EBI-005 for the treatment of dry eye disease (DED) and severe allergic conjunctivitis by targeting the Interleukin 1 receptor. The company is pioneering the creation of a topical rather than injectable Interleukin 1 receptor blocker.1 According to Medical Director Michael Goldstein, MD, MBA (written communication, May 2013), EBI-005 will continue phase 2 trials later this year. Per the company’s press release on June 28, 2013, the drug has achieved excellent results thus far in a phase 1b/2a study. Patients reportedly experienced a statistically significant improvement in DED, and EBI-005 was safe and well tolerated.

Rebamipide ophthalmic suspension (OPC-12759; Otsuka Pharmaceuticals) is currently in phase 3 trials in the United States.2 The drug enhances mucin secretion and is currently approved for the treatment of DED in Japan.2 Per the company’s press release on May 6, 2011, the drug has been superior to sodium hyaluronate.

According to a press release from R-Tech Ueno on April 26, 2013, the company received FDA approval to initiate phase 1 and 2 clinical trials of its compound RU-101, which contains recombinant human serum albumin and has downstream effects on tear production.

Lifitegrast (SAR 1118) prevents protein from binding to the cell, thereby inhibiting T-cell activation and the inflammatory cascade.3 According to a press release from SARcode Bioscience on October 23, 2012, the first phase 3 trial, which concluded in May 2012, demonstrated the drug’s superiority to placebo without serious adverse effects.4 Per the same announcement, a safety study (SONATA) is underway, and a second phase 3 trial (OPUS-2) is recruiting patients.5,6 Shire recently acquired SARcode Bioscience, along with global rights for lifitegrast. Shire anticipates launching the drug in the United States as early as 2016.7

Anti-infective Agents

Two companies are conducting trials of drugs for use against adenoviral conjunctivitis. Foresight Biotherapeutics is developing FST-100, which is the subject of an ongoing phase 2 study.8 FST-100 uses the company’s proprietary platform of povidone-iodine combined with dexamethasone.9

According to a press release from NovaBay Pharmaceuticals on April 8, 2013, the company began a phase 2b trial of Auriclosene (NVC-422), which enhances oxidative burst to destroy microbes.10 The trial will take place in multiple countries; the study just enrolled its first Brazilian patient in April 2013.

“The drug development pipeline is robust and bullish for anterior segment disease.”

BY F. FALLON UKPE, MD, MBA, AND JAI G. PAREKH, MD, MBA

The future is awesome.
Antiinflammatory Drugs

Mapracorat is under development by Bausch + Lomb. This selective glucocorticoid receptor agonist blocks the production of inflammatory mediators such as cytokines and prostaglandin.11 Two ongoing phase 3 trials are studying Mapracorat’s efficacy at treating pain and inflammation after cataract surgery.12,13

According to a press release on April 9, 2013, EyeGate Pharma is developing EGP-437, a corticosteroid that showed results equal to those of prednisolone acetate 1% for treating uveitis in phase 3 studies. The same compound is in phase 2 trials for the treatment of DED and in phase 1 trials for the treatment of scleritis.14

InSite Vision has three compounds with antiinflammatory indications: ISV-502 (AzaSite Plus) to treat blepharitis, ISV-303 (BromSite) to treat pain and inflammation after cataract surgery, and ISV-305 (DexaSite) to treat nonbacterial blepharitis and ocular inflammation.15 According to a press release on March 25, 2013, the company received special permission to launch the Dual Ophthalmic Agents Used in Blepharitis (DOUBLE) study for the simultaneous phase 3 evaluation of AzaSite Plus and DexaSite in the same trial. Results are expected by mid-2013. Per the company’s March 19, 2013, press release, BromSite has completed a phase 3 clinical trial, which showed that the drug is efficacious and superior to first-line treatment for postoperative pain and inflammation. InSite Vision announced on March 18, 2013, that it will begin another phase 3 trial to prepare for approval in the United States and Europe.

GLAUCOMA

Rho-associated Protein Kinase Inhibitors

A promising new class of drugs under development is called the Rho-associated protein kinase (ROCK) inhibitors.16 They modify the actin cytoskeleton to increase aqueous outflow, thereby lowering IOP.17 Additionally, these drugs have been found to enhance blood flow to the optic nerve.16 Multiple drugs in this category are in the pipeline.

Aerie Pharmaceuticals is developing AR-13324, AR-12286, and PG286 (combination therapy with AR-12286 and travoprost). All three are in phase 2 studies, and in November 2012, the company reported positive phase 2a results for both AR-13324 and AR-12286.3,18 In February 2013, Aerie began a study to

---

**Table: The Next Generation of Anterior Segment Pharmaceuticals**

<table>
<thead>
<tr>
<th>Drug</th>
<th>Company</th>
<th>Indication</th>
<th>Mechanism</th>
</tr>
</thead>
<tbody>
<tr>
<td>AzaSite Plus</td>
<td>InSite Vision</td>
<td>Blepharitis</td>
<td>Combines dexamethasone and azithromycin with DuraSite, the company’s extended drug delivery formulation</td>
</tr>
<tr>
<td>BromSite</td>
<td>InSite Vision</td>
<td>Pain and inflammation after cataract surgery</td>
<td>Combines bromfenac with DuraSite, the company’s extended drug delivery formulation</td>
</tr>
<tr>
<td>DexaSite</td>
<td>InSite Vision</td>
<td>Nonbacterial blepharitis, inflammation</td>
<td>Combines dexamethasone with DuraSite, the company’s extended drug delivery formulation</td>
</tr>
<tr>
<td>EGP-437</td>
<td>EyeGate Pharma</td>
<td>Uveitis</td>
<td>Iontophoresis technology increases the amount of the specially formulated dexamethasone drug to the eye</td>
</tr>
<tr>
<td>Latanoprostene bunod</td>
<td>Bausch + Lomb</td>
<td>Glaucoma</td>
<td>Prostaglandin F2 analogue that donates nitric oxide</td>
</tr>
<tr>
<td>Lifitegrast</td>
<td>Shire (formerly SARcode Bioscience)</td>
<td>Dry eye disease</td>
<td>Inhibits T-cell inflammation by inhibiting binding of two cell-surface proteins that mediate the inflammatory cascade</td>
</tr>
<tr>
<td>Mapracorat</td>
<td>Bausch + Lomb</td>
<td>Antiinflammatory</td>
<td>Selective glucocorticoid receptor agonist</td>
</tr>
<tr>
<td>Rebamipide</td>
<td>Otsuka Pharmaceuticals</td>
<td>Dry eye disease</td>
<td>Enhances mucin secretion</td>
</tr>
</tbody>
</table>

*aSummary of the compounds that are currently in phase 3 clinical trials for which studies may be complete and that may enter the market within the next few years.*
The future of eye care therapeutics is bright. The drugs in development are being designed to address the growing clinical needs of patients while minimizing side effects.

**Prostaglandin Analogue**

On January 29, 2013, Bausch + Lomb announced that it is developing latanoprostene bunod (BOL-303259-X). The mechanism by which this drug lowers IOP is unique compared to other medications on the market and the ROCK inhibitors: latanoprostene bunod is a prostaglandin F2 analogue that works by donating nitric oxide. ROCK inhibitors: latanoprostene bunod is a prostaglandin that limits dose escalation in trials. A phase 2 study of Amakem’s drug candidate AMA0076 began in the fall of 2012 and is currently recruiting candidates. According to the company’s press release on September 27, 2012, preclinical studies demonstrated superior IOP-lowering results with this agent versus latanoprost but without hyperemia—a major side effect of other ROCK inhibitors in development that limits dose escalation in trials.

**CONCLUSION**

The future of eye care therapeutics is bright. The drugs in development are being designed to address the growing clinical needs of patients while minimizing side effects.

This article was reprinted with permission from Cataract & Refractive Surgery Today’s July 2013 edition.

---

F. Fallon Ukpe, MD, MBA, a graduate of Duke University’s Combined MD-MBA Program, is an associate at McKinsey & Co. She acknowledged no financial interest in any of the products mentioned herein.

---


Jai G. Parekh, MD, MBA, is the managing partner at Brar-Parekh Eye Associates in Woodland Park, New Jersey, and chief of cornea and external diseases/chief of the Research Institute at St. Joseph’s HealthCare System, located in Wayne/Paterson, New Jersey. Dr. Parekh is also a clinical associate professor of ophthalmology on the Cornea Service at the New York Eye & Ear Infirmary in New York City. He is a consultant to and a speaker for Alcon Laboratories, Inc.; Allergan, Inc.; and Bausch + Lomb. He acknowledged no financial interest in the other products or companies mentioned herein. Dr. Parekh may be reached at (973) 785-2050: kerajai@gmail.com.